Results 81 to 90 of about 1,869,696 (352)
Arsenic is a potent co-mutagen of ultraviolet light
Communications Biology, 2023 Arsenic enhances the carcinogenicity of ultraviolet radiation (UVR). However, the mechanisms of arsenic-driven oncogenesis are not well understood. Here, we utilize experimental systems to investigate the carcinogenic and mutagenic properties of co ...
Rachel M. Speer +8 more
doaj +1 more source
The mutational signature of chronic lymphocytic leukemia [PDF]
Biochemical Journal, 2016 Advances in next-generation sequencing technologies continue to unravel the cancer genome, identifying key biological pathways important for disease pathogenesis and clinically relevant genetic lesions. These studies have provided unprecedented resolution of the cancer genome, facilitating significant advances in the ability to detect many cancers, and
Helen, Parker, Jonathan C, Strefford
openaire +2 more sources
Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma [PDF]
, 2016 Immunotherapy approaches for pancreatic ductal adenocarcinoma (PDAC) have met with limited success. It has been postulated that a low mutation load may lead to a paucity of T cells within the tumor microenvironment (TME).
Alvarez, Hector A. +13 more
core +1 more source
Sigflow: an automated and comprehensive pipeline for cancer genome mutational signature analysis
bioRxiv, 2020 Summary Mutational signatures are recurring DNA alteration patterns caused by distinct mutational events during the evolution of cancer. In recent years, several bioinformatics tools are available for mutational signature analysis.
Shixiang Wang +3 more
semanticscholar +1 more source
Organoids in pediatric cancer research
FEBS Letters, EarlyView.Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley +1 more source
Cancer Medicine, 2023 Purpose This study aimed to define the gene signature associated with response to neoadjuvant chemoradiotherapy (nCRT), or chemoradiosensitivity (CRS) signature, in rectal cancer, and investigate the correlation between the CRS signature and ...
Seung Hyuck Jeon, Eui Kyu Chie
doaj +1 more source
APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy. [PDF]
, 2019 Tumor-associated neo-antigens are mutated peptides that allow the immune system to recognize the affected cell as foreign. Cells carrying excessive mutation load often develop mechanisms of tolerance.
Boichard, Amélie +8 more
core
The Caenorhabditis elegans DPF‐3 and human DPP4 have tripeptidyl peptidase activity
FEBS Letters, EarlyView.The dipeptidyl peptidase IV (DPPIV) family comprises serine proteases classically defined by their ability to remove dipeptides from the N‐termini of substrates, a feature that gave the family its name. Here, we report the discovery of a previously unrecognized tripeptidyl peptidase activity in DPPIV family members from two different species.
Aditya Trivedi, Rajani Kanth Gudipati
wiley +1 more source
BRCA1-associated structural variations are a consequence of polymerase theta-mediated end-joining
Nature Communications, 2020 Cancer mutational signatures have been associated with defects in genome maintenance pathways. Here the authors, by using a worm germline mutagenesis model defective of human orthologue BRCA-1, identify polymerase theta-mediated end-joining (TMEJ) as ...
J. A. Kamp +3 more
doaj +1 more source
Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy. [PDF]
, 2019 Solid tumours are infiltrated by effector T cells with the potential to control or reject them, as well as by regulatory T (Treg) cells that restrict the function of effector T cells and thereby promote tumour growth1.
Cadilha, Bruno L +16 more
core +2 more sources